Study Finds No Limit to Cardiovascular Benefits of Exercise
Physical activity is not only associated with a lower risk of cardiovascular disease, but there is no threshold for that association, with the lowest risk of cardiovascular disease seen for those who are most active, according to a new study published this week in PLOS Medicine by Terence Dwyer of University of Oxford, UK, and colleagues.
Research has shown that there is an inverse association between self-reported physical activity and the occurrence of cardiovascular disease. However, there is uncertainty about the range of this association, especially at the highest levels of physical activity. In the new study, researchers used data from 90,211 UK Biobank participants without prior cardiovascular disease who agreed to wear an accelerometer to measure their physical activity over a 7-day period in 2013 through 2015.
Participants in the lowest category of physical activity smoked more, had higher body mass index and C-reactive protein, and were most often diagnosed with hypertension. Overall, there were 3,617 cases of cardiovascular disease diagnosed in participants during an average of 5.2 years of follow-up. People in every increasing quartile of physical activity, for moderate-intensity activity, vigorous-intensity activity and total physical activity, were less likely to have cardiovascular disease.
Clear Benefits Even at Highest Activity Levels
For instance, compared to those in the lowest quartile, those in the second quartile of moderate-intensity exercise were 71% as likely to be diagnosed with cardiovascular disease (95% CI 0.65-0.77), those in the third quartile were 59% as likely (95% CI 0.54-0.65) and those in the highest quartile were 46% as likely (95% CI 0.41-0.51). While potential confounders were taken into consideration, the possibility of unknown confounders or reverse causality cannot be completely ruled out in the current study.
Associate Professor Aiden Doherty, from the University of Oxford’s Nuffield Department of Population Health and one of the lead authors of the study, said: “This is the largest ever study of exquisite device-measured physical activity and cardiovascular disease. It shows that physical activity is probably even more important for the prevention of cardiovascular disease than we previously thought. Our findings lend further weight to the new WHO guidelines on physical activity which recommend at least 150 to 300 minutes of moderate to vigorous aerobic activity per week for all adults.”
Professor Terry Dwyer, from the University of Oxford’s Nuffield Department of Women’s & Reproductive Health and lead author of the study, said: “The results of this study enhance confidence that physical activity is likely to be an important way of preventing cardiovascular disease. The potential risk reduction estimated in those engaging in relatively high levels of activity is substantial and justifies a greater emphasis on measures to increase levels of physical activity in the community.”
Dr. Rema Ramakrishnan, from The University of Oxford’s Nuffield Department of Women’s & Reproductive Health and the first author of this study said: “We are confident about the study findings because physical activity was objectively assessed by a more valid tool that can capture frequency, intensity, and duration of physical activity rather than self-reported by the participants. We were also fortunate to have access to data from the UK Biobank study, a rich data source that could answer this question.”
Reference: “Accelerometer measured physical activity and the incidence of cardiovascular disease: Evidence from the UK Biobank cohort study” by Rema Ramakrishnan, Aiden Doherty, Karl Smith-Byrne, Kazem Rahimi, Derrick Bennett, Mark Woodward, Rosemary Walmsley and Terence Dwyer, 12 January 2021, PLOS Medicine.
DOI: 10.1371/journal.pmed.1003487
Funding: AD is supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), the Alan Turing Institute and the British Heart Foundation (grant number SP/18/4/33803), and Health Data Research UK, an initiative funded by UK Research and Innovation, Department of Health and Social Care (England) and the devolved administrations, and leading medical research charities. RW is supported by a Medical Research Council Industrial Strategy Studentship [grant number MR/S502509/1]. Computation used the Oxford Biomedical Research Computing (BMRC) facility, a joint development between the Wellcome Centre for Human Genetics and the Big Data Institute supported by Health Data Research UK and the NIHR Oxford Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NIHR. KR is supported by the National Institute of Health Research (NIHR) Oxford Biomedical Research Centre. KR further receives grants from the Oxford Martin School, University of Oxford as well as the PEAK Urban program from the UKRI’s Global Challenge Research Fund Grant Ref: ES/P011055/1 and the British Heart Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: KR has in the past received personal fees as Associate Editor for PLOS Medicine and as Associate Editor, is in receipt of Personal Fees from BMJ Heart. MW is a consultant to Amen and Kirin. RW is supported by a Medical Research Council Industrial Strategy Studentship (grant number MR/S502509/1). The Medical Research Council had no role in the study design; collection, analysis, and interpretation of data; writing of the paper; and/or decision to submit for publication.
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.